Xin Nakanishi, Ph.D. has served as a member of Oncternal’s board of directors since 2018. She has served as Chief Executive Officer of Shanghai Pharma Biotherapeutics USA Inc since July 2018. Dr. Nakanishi previously served as a venture partner at BioVENTURE, a portfolio advisor at Huya Bioscience International, a biology director at Phenomix Inc, a senior scientist at Pfizer, and a group leader at Immusol Inc. Dr. Nakanishi holds a Ph.D in molecular Biology from the University of Kansas.